Stock Scorer

Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics, Inc. reported revenue of 7.7M USD for the quarter ending 30 June 2026, down 46.2% from 14.2M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 7.7M -46.2%
Gross Profit Q4 '19 · ending 31 December 2019 10.9M +38.8%
Operating Income Q2 '26 · ending 30 June 2026 -112.8M —
Net Income Q2 '26 · ending 30 June 2026 -106.6M —
Cost of Revenue Q4 '19 · ending 31 December 2019 0 —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -83.1M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -84.9M —
Shares Outstanding Q2 '26 · ending 30 June 2026 133.5M +29.0%
EPS Q2 '26 · ending 30 June 2026 -3.35 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 67.7M-441M-412.7M-395.9M
20242024-12-31 57.9M-534.3M-519M-354.7M
20232023-12-31 36.3M-515.3M-481.2M-408.1M
20222022-12-31 52.1M-458.2M-474.2M-346.8M
20212021-12-31 33.1M-267.9M-267.9M-237.8M
20202020-12-31 58M-136.6M-134.2M-53.5M
20192019-12-31 43.1M-106.4M-474.2M-110M
20182018-12-31 30.4M-90.9M-85.3M-67.6M
20172017-12-31 26.1M-69.6M-67.5M-75.4M
20162016-12-31 16.5M-32.2M-31.6M29.9M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-307.7M
Q1 '262026-03-3115M
Q4 '252025-12-3123M
Q3 '252025-09-3013.8M
Q2 '252025-06-3014.2M
Q1 '252025-03-3116.6M
Q4 '242024-12-3112.9M
Q3 '242024-09-309.1M
Q2 '242024-06-307M
Q1 '242024-03-3128.9M
Q4 '232023-12-310
Q3 '232023-09-3012M
Q2 '232023-06-3013.6M
Q1 '232023-03-3112.6M
Q4 '222022-12-3113.6M
Q3 '222022-09-3013.3M
Q2 '222022-06-3014M
Q1 '222022-03-3111.3M
Q4 '212021-12-3112.9M
Q3 '212021-09-307.2M

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q4 '192019-12-3110.9M
Q3 '192019-09-3010.6M
Q2 '192019-06-3011.1M
Q1 '192019-03-3110.4M
Q4 '182018-12-317.9M
Q3 '182018-09-307.4M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-112.8M
Q1 '262026-03-31-100.5M
Q4 '252025-12-31-98.7M
Q3 '252025-09-30-111.5M
Q2 '252025-06-30-110M
Q1 '252025-03-31-120.8M
Q4 '242024-12-31-136.4M
Q3 '242024-09-30-144.8M
Q2 '242024-06-30-139M
Q1 '242024-03-31-114M
Q4 '232023-12-31-139.9M
Q3 '232023-09-30-131.1M
Q2 '232023-06-30-132.3M
Q1 '232023-03-31-112M
Q4 '222022-12-31-110.1M
Q3 '222022-09-30-105.5M
Q2 '222022-06-30-98.3M
Q1 '222022-03-31-144.2M
Q4 '212021-12-31-80.4M
Q3 '212021-09-30-72M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-106.6M
Q1 '262026-03-31-96.2M
Q4 '252025-12-31-95.8M
Q3 '252025-09-30-101.3M
Q2 '252025-06-30-101.3M
Q1 '252025-03-31-114.3M
Q4 '242024-12-31-128.9M
Q3 '242024-09-30-135.7M
Q2 '242024-06-30-147M
Q1 '242024-03-31-107.4M
Q4 '232023-12-31-132.2M
Q3 '232023-09-30-122.2M
Q2 '232023-06-30-123.7M
Q1 '232023-03-31-103.1M
Q4 '222022-12-31-113.4M
Q3 '222022-09-30-113.2M
Q2 '222022-06-30-100.7M
Q1 '222022-03-31-146.9M
Q4 '212021-12-31-81.2M
Q3 '212021-09-30-71.6M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q4 '192019-12-310
Q3 '192019-09-300
Q2 '192019-06-300
Q1 '192019-03-310
Q4 '182018-12-310
Q3 '182018-09-300

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-83.1M
Q1 '262026-03-31-117.3M
Q4 '252025-12-31-69.3M
Q3 '252025-09-30-76.9M
Q2 '252025-06-30-99.6M
Q1 '252025-03-31-148.9M
Q4 '242024-12-31-85.2M
Q3 '242024-09-30-84.8M
Q2 '242024-06-30-58.2M
Q1 '242024-03-31-120.7M
Q4 '232023-12-31-93.1M
Q3 '232023-09-30-101.4M
Q2 '232023-06-30-90.3M
Q1 '232023-03-31-109.3M
Q4 '222022-12-31-89.9M
Q3 '222022-09-30-78.5M
Q2 '222022-06-30-85.1M
Q1 '222022-03-31-79.8M
Q4 '212021-12-31-54.7M
Q3 '212021-09-30-65M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-84.9M
Q1 '262026-03-31-117.4M
Q4 '252025-12-31-69.4M
Q3 '252025-09-30-76.9M
Q2 '252025-06-30-99.9M
Q1 '252025-03-31-149.7M
Q4 '242024-12-31-86.2M
Q3 '242024-09-30-86.1M
Q2 '242024-06-30-59.2M
Q1 '242024-03-31-123.2M
Q4 '232023-12-31-94.6M
Q3 '232023-09-30-105.7M
Q2 '232023-06-30-94.6M
Q1 '232023-03-31-113.2M
Q4 '222022-12-31-93.8M
Q3 '222022-09-30-82.8M
Q2 '222022-06-30-89.1M
Q1 '222022-03-31-81.2M
Q4 '212021-12-31-57.5M
Q3 '212021-09-30-69.6M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30133.5M
Q1 '262026-03-31118.5M
Q3 '252025-09-30110.2M
Q2 '252025-06-30103.7M
Q1 '252025-03-31103.5M
Q3 '242024-09-30101M
Q2 '242024-06-3097M
Q1 '242024-03-3195.5M
Q3 '232023-09-3088.6M
Q2 '232023-06-3088.2M
Q1 '232023-03-3187.8M
Q3 '222022-09-3076M
Q2 '222022-06-3075.8M
Q1 '222022-03-3174.8M
Q3 '212021-09-3073.7M
Q2 '212021-06-3068.2M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-3.35
Q1 '262026-03-31-3.53
Q4 '252025-12-31-3.82
Q3 '252025-09-30-4.26
Q2 '252025-06-30-4.68
Q1 '252025-03-31-5.22
Q4 '242024-12-31-5.24
Q3 '242024-09-30-5.44
Q2 '242024-06-30-5.48
Q1 '242024-03-31-5.36
Q4 '232023-12-31-5.41
Q3 '232023-09-30-5.33
Q2 '232023-06-30-5.44
Q1 '232023-03-31-5.37
Q4 '222022-12-31-6.16
Q3 '222022-09-30-5.88
Q2 '222022-06-30-5.36
Q1 '222022-03-31-5.04
Q4 '212021-12-31-3.77
Q3 '212021-09-30-3.36